Cargando…
Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis
The purpose of this study is to characterize adverse events (AEs) of clinical interest reported with ceftolozane-tazobactam and ceftazidime-avibactam, as an aid in monitoring patients affected by severe multidrug-resistant Gram-negative infections. We queried the worldwide FDA Adverse Event Reportin...
Autores principales: | Gatti, Milo, Raschi, Emanuel, De Ponti, Fabrizio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139903/ https://www.ncbi.nlm.nih.gov/pubmed/33415492 http://dx.doi.org/10.1007/s10096-020-04149-3 |
Ejemplares similares
-
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
por: Raschi, Emanuel, et al.
Publicado: (2020) -
Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: insight from a pharmacovigilance study
por: Gatti, Milo, et al.
Publicado: (2019) -
Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis
por: Gatti, Milo, et al.
Publicado: (2020) -
Bone fracture as a novel immune‐related adverse event with immune checkpoint inhibitors: Case series and large‐scale pharmacovigilance analysis
por: Filippini, Daria Maria, et al.
Publicado: (2021) -
Liver Injury with Nintedanib: A Pharmacovigilance–Pharmacokinetic Appraisal
por: Raschi, Emanuel, et al.
Publicado: (2022)